M. Peter Lance, MD, FRCP, named UACC Interim Deputy Director - Phoenix

M. Peter Lance, MD, FRCP
M. Peter Lance, MD, FRCP

M. Peter Lance, MD, FRCP, Professor of Medicine, Molecular and Cellular Biology and Public Health at UA, and the UACC’s Chief Cancer Prevention and Control Officer, has been named Interim Deputy Director for the University of Arizona Cancer Center at St. Joseph’s Hospital and Medical Center/Dignity Health project.
As Interim Deputy Director - Phoenix, in conjunction with the UACC-St. Joseph's team, Dr. Lance will coordinate establishment of the clinical and translational faculty for UACC-Phoenix, which will include recruitment of more than 70 academic cancer specialists over the next 10 years. He is part of the team that is establishing the UACC presence at St. Joseph's now with the intent of building a robust program that will be ready to move to the new UACC building on the College of Medicine — Phoenix campus, which is scheduled to open in Summer 2015. Dr. Lance will lead integration of UACC clinical research activities in Phoenix with UACC basic, translational and clinical research in Tucson.
"Professor Lance is a consummate physician scientist with impeccable clinical and translational cancer research credentials. We are elated that he has agreed to take on the pivotal role of Interim Deputy Director, overseeing the rapid development of our clinical and translational research capabilities in Phoenix and northern Arizona. We feel strongly that there is no better person to accomplish task," said David S. Alberts, MD, UACC Director.

Dr. Lance obtained his undergraduate and medical degrees from the University of Cambridge, England. He completed residency and fellowship training in internal medicine and gastroenterology in England at the Universities of Birmingham and London. He came to the US in 1981 as a postdoctoral fellow at the University of California, San Francisco. In 1982, he moved to a junior faculty position at Brown University where he further developed his research interests in gastrointestinal oncology and became Board Certified in Internal Medicine and Gastroenterology. In 1987, Dr. Lance was recruited to a joint appointment at the University of Buffalo and Roswell Park Cancer Institute.

Over the next 14 years he progressed to the rank Professor of Medicine, and Physiology and Biophysics, and became Chief of the Division of Gastroenterology. He was a staff physician at Roswell Park Cancer Institute. He obtained NIH and VA Merit review funding for his studies of the role of sialyltransferases in the development and progression of colorectal cancer. He was site Principal Investigator for the NCI's Polyp Prevention Trial, to which almost 300 patients were randomized from Buffalo. 
Dr. Lance joined the University of Arizona Cancer Center in 2001. From 2005-11, he was leader of the Center's Cancer Prevention and Control Program and serves now as the Chief Cancer Prevention and Control Officer. His NCI-funded clinical and translational research in Arizona has focused on the prevention and early detection of colorectal cancer. He was one of the leaders of the first NCI multicenter study of fecal DNA for colorectal cancer screening.

He assumed leadership of the University of Arizona’s longstanding Colon Cancer Prevention Program Project. This includes a randomized trial of celecoxib and selenium supplementation for the prevention of colorectal polyp recurrence in 1,824 participants that will be completed in 2013; he has R01 funding to study the effects of selenium supplementation on type 2 diabetes risk in this study cohort. He is Principal Investigator of an R01 to investigate the effects of selenium and vitamin E on colorectal neoplasia-related endpoints in the 35,000 participants of the SELECT Trial of these interventions for prostate cancer prevention.
Dr. Lance’s service and outreach efforts include piloting CT colonography for colorectal cancer screening in Native Americans of the Navajo Nation. He is Medical Director for the Arizona Department of Health Services colorectal cancer screening program. Dr. Lance serves as medical director of the UA CaTS Clinical Research Unit and is currently Chair of the UA Committee on Promotion and Tenure.  He is an elected Fellow of the Royal College of Physicians of London. He was the 2012 recipient of the University of Arizona Cancer Center Sidney E. Salmon Distinguished Senior Investigator Award.